Improving the accuracy of pancreatic cancer clinical staging by exploitation of nanoparticle-blood interactions: A pilot study
Pancreatic ductal adenocarcinoma (PDAC) early diagnosis is crucial and new, cheap and user-friendly techniques for biomarker identification are needed. “Protein corona” (PC) is emerging a new bio-interface potentially useful in tumor early diagnosis. In a previous investigation, we showed that relevant differences between the protein pat terns of PCs formed on lipid NPs after exposure to PDAC and non-cancer plasma samples exist. To extend that research, We performed this pilot study to investigate the effect of PDAC tumor size and distant metastases on PC composition.
Source: Pancreatology - Category: Gastroenterology Authors: D. Caputo, M. Cartillone, C. Cascone, D. Pozzi, L. Digiacomo, S. Palchetti, G. Caracciolo, R. Coppola Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Gastroenterology | Nanotechnology | Pancreas | Pancreatic Cancer | Study